| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
| US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
Ortikos is owned by Sun Pharm Inds Inc.
Ortikos contains Budesonide.
Ortikos has a total of 2 drug patents out of which 0 drug patents have expired.
Ortikos was authorised for market use on 13 June, 2019.
Ortikos is available in capsule, extended release;oral dosage forms.
Ortikos can be used as treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon.
The generics of Ortikos are possible to be released after 09 September, 2036.
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 13 June, 2019
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ORTIKOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic